Stoke Therapeutics
STOK
197 hedge funds and large institutions have $2.49B invested in Stoke Therapeutics in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 77 increasing their positions, 57 reducing their positions, and 29 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 57
7.95% more ownership
Funds ownership: 110.21% → 118.17% (+8%)
8% more capital invested
Capital invested by funds: $2.31B → $2.49B (+$180M)
3% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 29
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 198 → 197 (-1)
27% less call options, than puts
Call options by funds: $736K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$69.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$20.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.5M |
| 5 |
BlackRock
New York
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$23.3M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.59M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$9.09M |
| 4 |
Goldman Sachs
New York
|
-$8.2M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$7M |
STOK Hedge Fund Activity: Q2 2026 in Review
197 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2026, worth a combined $2.49B — up 7.8% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new STOK positions and 29 closed out — a net gain of 1 holder — while 77 added to existing stakes and 57 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $69.5M. The largest seller was Lynx1 Capital Management, cutting an estimated $23.3M.
- 197 institutional investors held Stoke Therapeutics (STOK) as of Q2 2026, down from 198 in Q1 2026.
- Funds reported $2.49B of Stoke Therapeutics stock for Q2 2026, up 7.8% quarter-over-quarter.
- 30 funds opened new Stoke Therapeutics positions in Q2 2026 and 29 closed out, a net change of +1 holder.
- The largest Stoke Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $69.5M added.
- The largest Stoke Therapeutics seller in Q2 2026 was Lynx1 Capital Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q2 2026.